BR9506559C8 - compostos de derivados tetracíclicos, isômero cis de derivados tetracíclicos, e, composição farmacêutica - Google Patents

compostos de derivados tetracíclicos, isômero cis de derivados tetracíclicos, e, composição farmacêutica

Info

Publication number
BR9506559C8
BR9506559C8 BRPI9506559A BR9506559A BR9506559C8 BR 9506559 C8 BR9506559 C8 BR 9506559C8 BR PI9506559 A BRPI9506559 A BR PI9506559A BR 9506559 A BR9506559 A BR 9506559A BR 9506559 C8 BR9506559 C8 BR 9506559C8
Authority
BR
Brazil
Prior art keywords
alkyl
compound
pharmaceutical composition
ring
represents hydrogen
Prior art date
Application number
BRPI9506559A
Other languages
English (en)
Portuguese (pt)
Other versions
BR9506559A (pt
Inventor
Claude-Marie Daugan Alain
Original Assignee
Icos Corp
Laboratoire Glaxo Wellcome S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10749089&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9506559(C8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Icos Corp, Laboratoire Glaxo Wellcome S A filed Critical Icos Corp
Publication of BR9506559A publication Critical patent/BR9506559A/pt
Publication of BR9506559C8 publication Critical patent/BR9506559C8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI9506559A 1994-01-21 1995-01-19 compostos de derivados tetracíclicos, isômero cis de derivados tetracíclicos, e, composição farmacêutica BR9506559C8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9401090A GB9401090D0 (en) 1994-01-21 1994-01-21 Chemical compounds
PCT/EP1995/000183 WO1995019978A1 (en) 1994-01-21 1995-01-19 Tetracyclic derivatives, process of preparation and use

Publications (2)

Publication Number Publication Date
BR9506559A BR9506559A (pt) 1997-10-28
BR9506559C8 true BR9506559C8 (pt) 2020-07-07

Family

ID=10749089

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9506559A BR9506559C8 (pt) 1994-01-21 1995-01-19 compostos de derivados tetracíclicos, isômero cis de derivados tetracíclicos, e, composição farmacêutica

Country Status (48)

Country Link
US (5) US5859006A (2)
EP (1) EP0740668B1 (2)
JP (3) JP3808095B2 (2)
KR (1) KR100357411B1 (2)
CN (2) CN1045777C (2)
AP (1) AP556A (2)
AT (1) ATE169018T1 (2)
AU (2) AU689205B2 (2)
BG (1) BG62733B1 (2)
BR (1) BR9506559C8 (2)
CA (1) CA2181377C (2)
CO (1) CO4340684A1 (2)
CZ (1) CZ286566B6 (2)
DE (2) DE10399006I2 (2)
DK (1) DK0740668T3 (2)
EE (1) EE03231B1 (2)
EG (1) EG25852A (2)
ES (1) ES2122543T3 (2)
FI (1) FI113176B (2)
GB (1) GB9401090D0 (2)
HR (1) HRP950023B1 (2)
HU (1) HU222494B1 (2)
IL (1) IL112384A (2)
IN (1) IN183942B (2)
IS (1) IS1888B (2)
LU (1) LU91017I2 (2)
LV (1) LV11690B (2)
MA (1) MA23433A1 (2)
MX (1) MX9602904A (2)
MY (1) MY114663A (2)
NL (1) NL300124I2 (2)
NO (2) NO306465B1 (2)
NZ (1) NZ279199A (2)
OA (1) OA10584A (2)
PE (1) PE49495A1 (2)
PL (1) PL179744B1 (2)
RO (1) RO117794B1 (2)
RU (1) RU2142463C1 (2)
SA (1) SA95150475B1 (2)
SG (1) SG49184A1 (2)
SI (1) SI0740668T1 (2)
SK (1) SK280879B6 (2)
SV (1) SV1995000002A (2)
TN (1) TNSN95004A1 (2)
TW (1) TW378210B (2)
UY (1) UY23893A1 (2)
WO (1) WO1995019978A1 (2)
ZA (1) ZA95424B (2)

Families Citing this family (221)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9514465D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
GB9511220D0 (en) * 1995-06-02 1995-07-26 Glaxo Group Ltd Solid dispersions
US6262059B1 (en) 1995-06-07 2001-07-17 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with quinazoline derivatives
US6200980B1 (en) 1995-06-07 2001-03-13 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl purinone derivatives
US6232312B1 (en) 1995-06-07 2001-05-15 Cell Pathways, Inc. Method for treating patient having precancerous lesions with a combination of pyrimidopyrimidine derivatives and esters and amides of substituted indenyl acetic acides
US6046216A (en) 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl pyridinone derivatives
US5874440A (en) 1995-06-07 1999-02-23 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl pyrimidinone derivatives
US6060477A (en) 1995-06-07 2000-05-09 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl cycloamino pyrimidinone derivatives
GB9514464D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
GB9514473D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
ES2175404T3 (es) 1996-05-10 2002-11-16 Icos Corp Derivados de carbolina.
US6331543B1 (en) * 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
US5958926A (en) * 1996-11-01 1999-09-28 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
US6071934A (en) 1997-03-25 2000-06-06 Cell Pathways, Inc. Indenyl hydroxamic acids, (hydroxy) ureas and urethanes for treating patients with precancerous lesions
WO1998058633A2 (en) 1997-06-23 1998-12-30 Queen's University At Kingston Microdose therapy of vascular conditions by no donors
US6403597B1 (en) * 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US6046199A (en) * 1998-01-14 2000-04-04 Cell Pathways, Inc. Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B]indole derivatives
US6410584B1 (en) 1998-01-14 2002-06-25 Cell Pathways, Inc. Method for inhibiting neoplastic cells with indole derivatives
US6268372B1 (en) 1998-09-11 2001-07-31 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones
US6326379B1 (en) 1998-09-16 2001-12-04 Bristol-Myers Squibb Co. Fused pyridine inhibitors of cGMP phosphodiesterase
IL132406A0 (en) * 1998-10-21 2001-03-19 Pfizer Prod Inc Treatment of bph with cgmp elevators
US6133271A (en) 1998-11-19 2000-10-17 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
US6187779B1 (en) 1998-11-20 2001-02-13 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
US6348032B1 (en) 1998-11-23 2002-02-19 Cell Pathways, Inc. Method of inhibiting neoplastic cells with benzimidazole derivatives
US6211220B1 (en) 1998-11-23 2001-04-03 Cell Pathways, Inc. Method for treating neoplasia with amino or pyridylamino cyclobutene derivatives
US6486155B1 (en) 1998-11-24 2002-11-26 Cell Pathways Inc Method of inhibiting neoplastic cells with isoquinoline derivatives
US6420410B1 (en) 1998-11-24 2002-07-16 Cell Pathways, Inc. Method for treating neoplasia by exposure to N,N′-substituted benzimidazol-2-ones
US6211177B1 (en) 1998-11-24 2001-04-03 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted 2-aryl-benzimidazole derivatives
US6358992B1 (en) 1998-11-25 2002-03-19 Cell Pathways, Inc. Method of inhibiting neoplastic cells with indole derivatives
WO2000056304A2 (en) * 1999-03-24 2000-09-28 Harbor Branch Oceanographic Institution, Inc. Anti-inflammatory uses of manzamines
ES2187234A1 (es) * 1999-04-30 2003-05-16 Lilly Icos Llc Forma de dosificacion oral para tratar la disfuncion sexual.
US6451807B1 (en) 1999-04-30 2002-09-17 Lilly Icos, Llc. Methods of treating sexual dysfunction in an individual suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction using a PDE5 inhibitor
US6943166B1 (en) * 1999-04-30 2005-09-13 Lilly Icos Llc. Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction
US7235625B2 (en) 1999-06-29 2007-06-26 Palatin Technologies, Inc. Multiple agent therapy for sexual dysfunction
EA004872B1 (ru) 1999-08-03 2004-08-26 ЛИЛЛИ АЙКОС эЛ-эЛ-Си β-КАРБОЛИНОВЫЕ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ
US6821975B1 (en) 1999-08-03 2004-11-23 Lilly Icos Llc Beta-carboline drug products
AP2002002455A0 (en) 1999-10-11 2002-06-30 Pfizer 5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)-dIhydropyrazolo[4,3-D] pyrimidin-7-ones as phosphodiesterase inhibitors.
TW200400821A (en) * 1999-11-02 2004-01-16 Pfizer Pharmaceutical composition (II) useful for treating or preventing pulmonary hypertension in a patient
US6562830B1 (en) 1999-11-09 2003-05-13 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl quinazolinone derivatives
US6376489B1 (en) * 1999-12-23 2002-04-23 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US20020013327A1 (en) * 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
JP2004500425A (ja) 2000-04-19 2004-01-08 リリー　アイコス　リミテッド　ライアビリティ　カンパニー パーキンソン病の処置に対する環状ｇｍｐ特異的ホスホジエステラーゼインヒビターの使用
UA74826C2 (en) * 2000-05-17 2006-02-15 Ortho Mcneil Pharm Inc ?-carboline derivatives as phosphodiesterase inhibitors
UA72611C2 (uk) * 2000-05-17 2005-03-15 Орто-Макнейл Фармацевтикал, Інк. Похідні заміщеного піролопіридинону, корисні як інгібітори фосфодіестерази
CA2411008C (en) * 2000-06-07 2006-04-11 Lilly Icos Llc Derivatives of 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione
EP1366049B1 (en) 2000-06-23 2006-06-21 Lilly Icos LLC Pirazino¬1'2':1,6|pyrido¬3,4-b|indole derivatives
ES2269408T3 (es) * 2000-06-23 2007-04-01 Lilly Icos Llc Inhibidores de fosfodiesterasa especifica de gmp ciclico.
EP1313736B1 (en) 2000-06-26 2005-07-27 Lilly Icos LLC Condensed pyrazindione derivatives as inhibitors of pde5
CN1252055C (zh) * 2000-07-24 2006-04-19 拜尔农作物科学股份公司 联苯甲酰胺类化合物
EP1305313A1 (en) * 2000-08-02 2003-05-02 Lilly Icos LLC Fused heterocyclic derivatives as phosphodiesterase inhibitors
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
WO2002028858A2 (en) * 2000-10-02 2002-04-11 Lilly Icos Llc Hexahydropyrazino `1'2' : 1, 6!- pyrido `3, 4-b! indole-1, 4-dione derivatives for the treatment of cardiovascular disorders and erectile disfunction
ES2248399T3 (es) 2000-10-02 2006-03-16 Lilly Icos Llc Derivados de piridoindol condensado.
US6548508B2 (en) 2000-10-20 2003-04-15 Pfizer, Inc. Use of PDE V inhibitors for improved fecundity in mammals
US6828473B2 (en) 2000-11-01 2004-12-07 Pfizer Inc. Modulation of PDE11A activity
EP1211313A3 (en) * 2000-11-01 2003-04-23 Pfizer Limited Modulation of PDE11A activity
ATE337320T1 (de) * 2000-11-06 2006-09-15 Lilly Icos Llc Indolderivate als pde5-inhibitoren
EP1383765B1 (en) * 2001-04-25 2006-12-13 Lilly Icos LLC Carboline derivatives as inhibitors of phosphodiesterase 5 (PDE5) for the treatment of cardiovascular diseases and erectile dysfunction
FR2824829B1 (fr) * 2001-05-16 2005-06-03 Macef Nouveaux derives de dihydroimidazo [5,1-a]-beta-carboline, leur procede de preparation et leur application a titre de medicament
WO2002098875A1 (en) * 2001-06-05 2002-12-12 Lilly Icos Llc Carboline derivatives as pde-5 inhibitors
WO2002098877A1 (en) * 2001-06-05 2002-12-12 Lilly Icos Llc Pyrazino 1',2':1,6 pyrido 3,4-b indole1,4-dione derivatives
MXPA03011080A (es) * 2001-06-05 2004-07-08 Lilly Icos Llc Compuestos tetraciclicos como inhibidores de pde5.
WO2003000691A1 (en) * 2001-06-21 2003-01-03 Lilly Icos Llc Carboline derivatives as pdev inhibitors
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
CA2465893A1 (en) * 2001-11-09 2003-05-22 Schering Corporation Polycyclic guanine derivative phosphodiesterase v inhibitors
PT1448562E (pt) * 2001-11-14 2007-08-31 Ortho Mcneil Pharm Inc Derivados da pirroloquinolona tetracíclica substituídos, úteis como inibidores da fosfodiesterase
US7276529B2 (en) 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7208516B2 (en) 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
CN1655820A (zh) * 2002-05-23 2005-08-17 辉瑞大药厂 Pde5抑制剂与ace抑制剂的药物组合
EP1719772A1 (en) 2002-05-31 2006-11-08 Schering Corporation Process for preparing xanthine phosphodiesterase v inhibitors and precursors thereof
GB0214784D0 (en) * 2002-06-26 2002-08-07 Pfizer Ltd Novel combination
AU2003256539B2 (en) * 2002-07-31 2010-03-04 Icos Corporation Modified pictet-spengler reaction and products prepared therefrom
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
US7323462B2 (en) 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
WO2004054560A1 (en) 2002-12-13 2004-07-01 Warner-Lambert Company Llc Alpha-2-delta ligand to treat lower urinary tract symptoms
MXPA05010373A (es) 2003-04-01 2005-12-05 Applied Research Systems Inhibidores de fosfodiesterasas en infertilidad.
EA008596B1 (ru) 2003-04-29 2007-06-29 Пфайзер Инк. 5,7-ДИАМИНОПИРАЗОЛО[4,3-d]ПИРИМИДИНЫ, ПОЛЕЗНЫЕ ПРИ ЛЕЧЕНИИ ГИПЕРТЕНЗИИ
EA012279B1 (ru) * 2003-05-22 2009-08-28 Никомед Гмбх Композиция, включающая ингибитор pde4 и ингибитор pde5
PL1644021T3 (pl) * 2003-06-13 2013-01-31 Ironwood Pharmaceuticals Inc Sposoby i kompozycje do leczenia zaburzeń żołądkowo-jelitowych
ES2427166T3 (es) 2003-06-23 2013-10-29 Ono Pharmaceutical Co., Ltd. Compuesto heterocíclico tricíclico novedoso
US7291640B2 (en) 2003-09-22 2007-11-06 Pfizer Inc. Substituted triazole derivatives as oxytocin antagonists
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
US20060018970A1 (en) * 2003-12-12 2006-01-26 Myogen, Inc. Enoximone formulations and their use in the treatment of cardiac hypertrophy and heart failure
WO2005068464A2 (en) * 2003-12-15 2005-07-28 Cadila Healthcare Limited Process for preparing tadalafil and its intermediates
BRPI0506994A (pt) 2004-01-22 2007-07-03 Pfizer derivados de triazol que inibem a atividade antagonista da vasopressina
US7649002B2 (en) 2004-02-04 2010-01-19 Pfizer Inc (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
CA2560538A1 (en) * 2004-03-22 2005-10-06 Myogen, Inc. (r)-enoximone sulfoxide and its use in the treatment of pde-iii mediated diseases
EP1737448A1 (en) * 2004-03-22 2007-01-03 Myogen, Inc. (s) - enoximone sulfoxide and its use in the treatment of pde-iii mediated diseases
DE602005011784D1 (de) 2004-04-07 2009-01-29 Pfizer Pyrazoloä4,3-düpyrimidine
WO2005116030A1 (en) * 2004-05-31 2005-12-08 Matrix Laboratories Ltd A process for the preparation of tadalafil
EP1776108A1 (en) * 2004-06-23 2007-04-25 Myogen, Inc. Enoximone formulations and their use in the treatment of pde-iii mediated diseases
CA2577442A1 (en) 2004-08-17 2006-03-02 The Johns Hopkins University Pde5 inhibitor compositions and methods for treating cardiac indications
EP1804582A4 (en) * 2004-10-28 2009-12-09 Reddys Lab Ltd Dr POLYMORPH SHAPES OF TADALAFIL
TW200630348A (en) * 2004-11-02 2006-09-01 Teva Pharma Tadalafil crystal forms and processes for preparing them
AR051780A1 (es) * 2004-11-29 2007-02-07 Japan Tobacco Inc Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos
WO2006068164A1 (ja) 2004-12-22 2006-06-29 Ono Pharmaceutical Co., Ltd. 三環式化合物およびその用途
EP1851222A1 (en) * 2005-02-25 2007-11-07 Teva Pharmaceutical Industries Ltd Process of synthesizing tadalafil
US7417044B2 (en) * 2005-02-25 2008-08-26 Teva Pharmaceutical Industries Ltd. Tadalafil having a large particle size and a process for preparation thereof
CA2599458A1 (en) * 2005-02-25 2006-08-31 Teva Pharmaceutical Industries Ltd. Process of purifying tadalafil
US20070088012A1 (en) * 2005-04-08 2007-04-19 Woun Seo Method of treating or preventing type-2 diabetes
EP1812435A2 (en) * 2005-04-12 2007-08-01 Teva Pharmaceutical Industries Ltd Preparation of tadalafil intermediates
NZ561746A (en) 2005-04-19 2011-09-30 Nycomed Gmbh Roflumilast for the treatment of pulmonary hypertension
US8506934B2 (en) 2005-04-29 2013-08-13 Robert I. Henkin Methods for detection of biological substances
BRPI0609225A2 (pt) 2005-05-12 2010-03-09 Pfizer formas cristalinas anidras de n-[1-(2-etoxietil)-5-(n-etil-n-metilamino)-7-(4-metilpiridi n-2-il-amino)-1h-pirazolo[4,3-d]pirimidina-3-carbonil] metanossulfonamida, composição farmacêutica compreendendo as mesmas e uso das mesmas
US20070010525A1 (en) * 2005-06-27 2007-01-11 Meyer Jackson Method and compositions for modulating neuropeptide hormone secretion
AU2006275702A1 (en) * 2005-07-29 2007-02-08 Concert Pharmaceuticals Inc. Novel pharmaceutical compounds
US7863274B2 (en) * 2005-07-29 2011-01-04 Concert Pharmaceuticals Inc. Deuterium enriched analogues of tadalafil as PDE5 inhibitors
ES2646326T3 (es) 2005-08-03 2017-12-13 Sprout Pharmaceuticals, Inc. Uso de flibanserina en el tratamiento de la obesidad
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP1928437A2 (en) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
US20070104792A1 (en) * 2005-09-13 2007-05-10 Elan Pharma International, Limited Nanoparticulate tadalafil formulations
ES3012497T3 (en) 2005-10-12 2025-04-09 Besins Healthcare Lu Sarl Improved testosterone gel and method of use
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
CA2626134C (en) 2005-10-29 2013-12-24 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
WO2007100387A2 (en) * 2005-11-03 2007-09-07 Dr. Reddy's Laboratories Ltd. Process for preparing tadalafil
WO2007056457A2 (en) 2005-11-09 2007-05-18 Combinatorx, Incorporated Methods, compositions, and kits for the treatment of medical conditions
US7202229B1 (en) * 2005-12-30 2007-04-10 Alan James Group, Llc. Aspirin formulation for cardiovascular health
US7201929B1 (en) * 2005-12-30 2007-04-10 Alan James Group, Llc. Aspirin formulation for cardiovascular health
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
EP1991212A1 (en) * 2006-03-08 2008-11-19 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2004644A1 (en) * 2006-03-24 2008-12-24 Glenmark Pharmaceuticals Limited Process for the preparation of tadalafil
US20080027072A1 (en) * 2006-04-20 2008-01-31 Ampla Pharmaceuticals, Inc. Potentiation of MC4 receptor activity
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
US20090291958A1 (en) * 2006-06-08 2009-11-26 Auspex Pharmaceuticals, Inc. Substituted PDE5 inhibitors
JP2009541443A (ja) 2006-06-30 2009-11-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 尿失禁及び関連疾患の治療のためのフリバンセリン
KR101140110B1 (ko) * 2006-07-07 2012-06-04 테바 파마슈티컬 인더스트리즈 리미티드 타달라필 및 하나 이상의 담체를 포함하는 고체 조성물
EP2046292B1 (en) 2006-07-21 2010-03-03 Novartis AG Formulations for benzimidazolyl pyridyl ethers
EP2054041A2 (en) 2006-08-14 2009-05-06 Boehringer Ingelheim International GmbH Formulations of flibanserin and method for manufacturing the same
IL197129A (en) 2006-08-25 2014-08-31 Boehringer Ingelheim Int Controlled release system and method for production
AR062501A1 (es) 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd Composiciones terapeuticas
EP2068872A1 (en) * 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
AU2007299920A1 (en) * 2006-09-19 2008-03-27 Braincells, Inc. PPAR Mediated Modulation of Neurogenesis
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
EP2101777B1 (en) 2006-12-12 2015-05-20 Gilead Sciences, Inc. Composition for treating a pulmonary hypertension
US8293489B2 (en) 2007-01-31 2012-10-23 Henkin Robert I Methods for detection of biological substances
CN101674728A (zh) * 2007-02-12 2010-03-17 Dmi生物科学公司 降低曲马多的副作用
CN101657101B (zh) * 2007-02-12 2013-12-11 Dmi生物科学公司 并存早泄和勃起功能障碍的治疗
WO2008103470A2 (en) * 2007-02-21 2008-08-28 Trustees Of Columbia University In The City Of New York Oncogenic-ras-signal dependent lethal compounds
KR20100012867A (ko) * 2007-04-25 2010-02-08 테바 파마슈티컬 인더스트리즈 리미티드 타다라필을 포함하는 고체 제형
FR2916200A1 (fr) * 2007-05-18 2008-11-21 Fourtillan Snc Nouveaux derives des 1,2,3,4,6,7,12,12a-octahydro pyrazino[1',2':1,6]pyrido[3,4-b]indoles, leur preparation et leur utilisation en therapeutique
DE102007028869A1 (de) 2007-06-22 2008-12-24 Ratiopharm Gmbh Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil
KR20100027170A (ko) * 2007-06-29 2010-03-10 랜박시 래보러터리스 리미티드 테트라사이클릭 화합물의 중간체의 제조 방법
EP2033962A1 (en) * 2007-08-22 2009-03-11 4Sc Ag Tetracyclic indolopyridines as EG5 inhibitors
CL2008002693A1 (es) 2007-09-12 2009-10-16 Boehringer Ingelheim Int Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad
US20090181975A1 (en) * 2008-01-15 2009-07-16 Forest Laboratories Holdings Limited Nebivolol in the treatment of sexual dysfunction
ITMI20080285A1 (it) * 2008-02-22 2009-08-23 Endura Spa Procedimento per la preparazione di esteri di acidi tetraidro-1h-betacarbolin-3-carbossilici
EP2107059A1 (en) 2008-03-31 2009-10-07 LEK Pharmaceuticals D.D. Conversion of tryptophan into ß-carboline derivatives
PL385356A1 (pl) 2008-06-03 2009-12-07 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania tadalafilu
US8580801B2 (en) 2008-07-23 2013-11-12 Robert I. Henkin Phosphodiesterase inhibitor treatment
EP2181997A1 (en) 2008-10-30 2010-05-05 Chemo Ibérica, S.A. A process for the preparation of tadalafil
DE102008063992A1 (de) 2008-12-19 2010-09-02 Lerner, Zinoviy, Dipl.-Ing. Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung
EP2379076B1 (en) 2008-12-23 2014-11-12 The Trustees of Columbia University in the City of New York Phosphodiesterase inhibitors and uses thereof
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
JP6074142B2 (ja) 2009-02-26 2017-02-01 タール ファーマシューティカルズ，インコーポレイテッド 医薬化合物の結晶化
GB0903493D0 (en) 2009-02-27 2009-04-08 Vantia Ltd New compounds
DE102009033396A1 (de) 2009-07-16 2011-01-20 Ratiopharm Gmbh Wässrige Lösung und gelatinierte Zusammensetzung umfassend einen Phosphodiesterase-5-Inhibitor sowie diesbezügliche Verfahren und Verwendung
UY33041A (es) 2009-11-27 2011-06-30 Bayer Schering Pharma Aktienegesellschaft Procedimiento para la preparaciòn de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo y su purificaciòn para el uso como principio activo farmacèutico
US20110136815A1 (en) 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
CN102970965A (zh) 2010-04-05 2013-03-13 Sk化学公司 含有pde5抑制剂的减少皮肤皱纹的合成物
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
NZ610012A (en) 2010-10-15 2015-05-29 Gilead Sciences Inc Compositions and methods of treating pulmonary hypertension
JP5816704B2 (ja) 2011-02-10 2015-11-18 インテルキム、ソシエダッド アノニマ テトラヒドロ−β−カルボリンから誘導される化合物を得る方法
RU2013141446A (ru) 2011-02-10 2015-03-20 Синтон Бв Фармацевтическая композиция, содержащая тадалафил и циклодекстрин
EP2672959A1 (en) 2011-02-10 2013-12-18 Synthon BV Granulated composition comprising tadalafil and a disintegrant
WO2012107092A1 (en) 2011-02-10 2012-08-16 Synthon Bv Pharmaceutical composition comprising tadalafil and a cyclodextrin
US20120123124A1 (en) * 2011-04-22 2012-05-17 Drug Process Licensing Associates, LLC Manufacturing process for Tadalafil from racemic or L-tryptophan
CN102180876B (zh) * 2011-05-28 2016-05-18 浙江华海药业股份有限公司 一种他达那非晶型i的制备方法
EP2535049A1 (en) 2011-06-17 2012-12-19 Proyecto de Biomedicina Cima, S.L. Tadalafil for the treatment of dementia
CN102367253B (zh) * 2011-09-20 2016-04-06 浙江华海药业股份有限公司 一种制备他达拉非晶型a的方法
US9402877B2 (en) 2011-11-04 2016-08-02 Xion Pharmaceuticals Corporation Methods and compositions for oral administration of melanocortin receptor agonist compounds
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
WO2013109738A1 (en) 2012-01-17 2013-07-25 The Trustees Of Columbia University In The City Of New York Novel phosphodiesterase inhibitors and uses thereof
WO2013109230A1 (en) 2012-01-18 2013-07-25 Mahmut Bilgic Pharmaceutical compositions comprising tadalafil
WO2013109225A1 (en) 2012-01-18 2013-07-25 Mahmut Bilgic Pharmaceutical tablet formulations comprising ceftibuten
WO2013109223A1 (en) 2012-01-18 2013-07-25 Mahmut Bilgic Particulate formulations of tadalafil in effervescent form
CN104168895B (zh) 2012-02-28 2020-02-21 首尔制药株式会社 包含西地那非作为活性成分的掩蔽苦味的高含量快速溶解膜
WO2014055801A1 (en) 2012-10-05 2014-04-10 Henkin Robert I Phosphodiesterase inhibitors for treating taste and smell disorders
US9750743B2 (en) 2012-12-04 2017-09-05 Aribio Inc. Composition comprising phosphodiesterase type 5 inhibitor for inhibiting apoptosis of nerve cells
KR101953735B1 (ko) 2012-12-14 2019-03-04 한미약품 주식회사 포스포다이에스터라제-5 억제제를 포함하는 츄정
EP2938343B1 (en) 2012-12-21 2018-09-12 Mayo Foundation For Medical Education And Research Methods and materials for treating calcific aortic valve stenosis
CN105102457A (zh) 2013-02-21 2015-11-25 阿德弗里奥药品有限责任公司 {4,6-二氨基-2-[1-(2-氟苄基)-1H-吡唑并[3,4-b]吡啶-3-基]嘧啶-5-基}甲基氨基甲酸甲酯的形式
CN103232451A (zh) * 2013-05-14 2013-08-07 张家港威胜生物医药有限公司 一种他达那非的简易制备工艺
ES2776353T3 (es) 2013-07-17 2020-07-30 Univ Columbia Inhibidores de la fosfodiesterasa novedosos y usos de los mismos
US20160317542A1 (en) 2013-12-09 2016-11-03 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
US10598672B2 (en) 2014-02-18 2020-03-24 Cyrano Therapeutics, Inc. Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
AR099416A1 (es) 2014-02-28 2016-07-20 Lilly Co Eli Terapia combinada para la hipertensión resistente
MX2016014384A (es) 2014-06-23 2017-01-20 Celgene Corp Apremilast para el tratamiento de una enfermedad del higado o una anormalidad en la funcion del higado.
EP2962684A1 (en) 2014-06-30 2016-01-06 Sanovel Ilac Sanayi ve Ticaret A.S. Orally disintegrating formulations of tadalafil
WO2016001143A1 (en) 2014-06-30 2016-01-07 Sanovel Ilac Sanayi Ve Ticaret A.S. Orally disintegrating formulations of tadalafil
CN104086546B (zh) * 2014-07-14 2016-08-17 福建广生堂药业股份有限公司 他达拉非的药用酸盐及其制备方法
EA035390B1 (ru) 2014-07-23 2020-06-05 КРКА, д.д., НОВО МЕСТО Совместный осадок тадалафила с фармацевтически приемлемыми эксципиентами, содержащая его фармацевтическая композиция и способ их получения
KR101645652B1 (ko) 2014-11-03 2016-08-08 (주)퓨젠바이오농업회사법인 세리포리아 락세라타에 의해 생산되는 세포외다당체를 유효성분으로 함유하는 성기능개선용 조성물
ES2774048T3 (es) * 2015-06-26 2020-07-16 Chongqing Dikang Erle Pharma Co Ltd Nuevo inhibidor de la fosfodiesterasa de tipo 5 y su aplicación
CN105541840B (zh) * 2015-12-31 2017-12-05 湖南千金湘江药业股份有限公司 关键中间体及其合成方法和在制备他达拉非方面的应用
CN105541835B (zh) * 2015-12-31 2017-12-05 湖南千金湘江药业股份有限公司 顺式四氢咔啉中间体及其合成方法和在制备他达拉非方面的应用
EP4620525A3 (en) 2016-12-14 2025-12-03 Respira Therapeutics, Inc. Methods and compositions for treatment of pulmonary hypertension and other lung disorders
CN106977516B (zh) * 2017-03-02 2019-06-18 山东裕欣药业有限公司 一种他达拉非的制备方法
WO2020210707A1 (en) 2019-04-10 2020-10-15 Mayo Foundation For Medical Education And Research Methods and materials for gender-dependent treatment of cardiovascular dysfunction
RU2692764C1 (ru) 2019-04-26 2019-06-27 Общество с ограниченной ответственностью "Балтфарма" Способ получения тадалафила
CN111995658B (zh) * 2019-05-27 2022-08-02 首都医科大学 Ldv修饰的五环哌嗪二酮及其制备和应用
CN114158266A (zh) 2019-07-15 2022-03-08 生物实验萨纽斯药物有限公司 化合物3-(苯并[d][1,3]二氧杂环戊烯-5-基)-7-(1-羟基丙-2-基)-1-(1H-吲哚-3-基)-6,7-二氢-3H-噁唑并[3,4-a]吡嗪-5,8-二酮的立体异构体及其作为抗肿瘤剂和磷酸二酯酶抑制剂的用途
CN110606847A (zh) * 2019-07-30 2019-12-24 中国医药集团总公司四川抗菌素工业研究所 一种他达拉非顺式中间体的制备方法及其应用
US11590209B2 (en) 2020-01-21 2023-02-28 Palatin Technologies, Inc. Use of bremelanotide in patients with controlled hypertension
JP7606530B2 (ja) 2020-03-24 2024-12-25 シラノ セラピューティクス， インコーポレイテッド コロナウイルス感染症による化学感覚機能障害の治療
WO2021245192A1 (en) 2020-06-04 2021-12-09 Topadur Pharma Ag Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof
KR20240117491A (ko) 2023-01-25 2024-08-01 주식회사 아리바이오 포스포디에스테라제 타입 ５ 저해제를 유효성분으로 포함하는 외상 후 스트레스 장애의 예방 또는 치료용 조성물
AU2024220563A1 (en) 2023-02-16 2025-08-14 University Of Rochester Improving glymphatic-lymphatic efflux
CN116715667A (zh) * 2023-06-20 2023-09-08 常州制药厂有限公司 一种他达拉非新晶型b及其制备方法
EP4684777A1 (en) 2024-07-24 2026-01-28 Adalvo Limited A fixed-dose pharmaceutical composition comprising (2s)-2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropanoic acid and (6r,12ar)-6-(1,3-benzodioxol-5-yl)-2-methyl-2,3,6,7,12,12a-hexahydropyrazino{1',2:1,6]pyrido[3,4-b]indole-1,4-dione

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3644384A (en) * 1969-06-09 1972-02-22 Sterling Drug Inc Certain 2-(alpha-haloacetyl) - 1 2 3 4-tetrahydro - 9h - pyrido(3 4-b)indole-3-carboxylates and derivatives
US3717638A (en) * 1971-03-11 1973-02-20 Sterling Drug Inc 1,2,3,4,6,7,12,12A-OCTAHYDRO-2-PHENYLPYRAZINO[2',1':6,1]PYRIDO[3,4-b]INDOLES AND INTERMEDIATES THEREFOR
US3917599A (en) * 1973-03-30 1975-11-04 Council Scient Ind Res 2-Substituted-1,2,3,4,6,7,12,12A-octahydropyrazino(2{40 ,1{40 :6,1)pyrido(3,4-B)indoles
GB1454171A (en) * 1973-10-19 1976-10-27 Council Scient Ind Res Tetracyclic compounds
US4273773A (en) * 1979-09-24 1981-06-16 American Home Products Corporation Antihypertensive tricyclic isoindole derivatives
EP0357122A3 (en) * 1988-08-29 1991-10-23 Duphar International Research B.V Use of beta-carbolines, their bio-isosteric benzofuran and benzothiophene analogues for the manufacture of a medicament having cytostatic properties
DE3830096A1 (de) * 1988-09-03 1990-03-15 Hoechst Ag Piperazindione mit psychotroper wirkung
GB9514465D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
US6046199A (en) * 1998-01-14 2000-04-04 Cell Pathways, Inc. Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B]indole derivatives
US6225315B1 (en) * 1998-11-30 2001-05-01 Pfizer Inc Method of treating nitrate-induced tolerance

Also Published As

Publication number Publication date
CA2181377C (en) 2002-05-28
JP2009102386A (ja) 2009-05-14
IS1888B (is) 2003-09-01
IS4252A (is) 1995-07-22
CZ286566B6 (cs) 2000-05-17
US6369059B1 (en) 2002-04-09
ES2122543T3 (es) 1998-12-16
PL179744B1 (pl) 2000-10-31
US20020119976A1 (en) 2002-08-29
DK0740668T3 (da) 1999-05-03
FI962927A7 (fi) 1996-07-19
PE49495A1 (es) 1996-01-10
AU707055B2 (en) 1999-07-01
SK94096A3 (en) 1997-04-09
FI962927A0 (fi) 1996-07-19
CN1224720A (zh) 1999-08-04
AP556A (en) 1996-11-07
DE69503753D1 (de) 1998-09-03
NO306465B1 (no) 1999-11-08
NO2003002I1 (no) 2003-01-22
RO117794B1 (ro) 2002-07-30
JP3808095B2 (ja) 2006-08-09
LV11690B (en) 1997-06-20
EG25852A (en) 2012-09-10
NL300124I1 (nl) 2003-07-01
BR9506559A (pt) 1997-10-28
SG49184A1 (en) 1998-05-18
BG100727A (bg) 1997-02-28
MY114663A (en) 2002-12-31
US6784179B2 (en) 2004-08-31
NL300124I2 (nl) 2003-11-03
IN183942B (2) 2000-05-20
FI113176B (fi) 2004-03-15
NO963015D0 (no) 1996-07-19
DE69503753T2 (de) 1999-01-21
DE10399006I1 (de) 2003-07-31
HU222494B1 (hu) 2003-07-28
OA10584A (en) 2002-08-26
TNSN95004A1 (fr) 1996-02-06
RU2142463C1 (ru) 1999-12-10
NO2003002I2 (no) 2005-03-21
JP2004217674A (ja) 2004-08-05
CO4340684A1 (es) 1996-07-30
DE10399006I2 (de) 2004-05-06
SI0740668T1 (en) 1999-02-28
EP0740668A1 (en) 1996-11-06
HRP950023A2 (en) 1998-04-30
NO963015L (no) 1996-09-09
KR100357411B1 (ko) 2003-02-05
AU689205B2 (en) 1998-03-26
AP9500712A0 (en) 1995-01-31
WO1995019978A1 (en) 1995-07-27
SA95150475B1 (ar) 2005-07-31
TW378210B (en) 2000-01-01
CN1045777C (zh) 1999-10-20
EE03231B1 (et) 1999-10-15
US6025494A (en) 2000-02-15
ZA95424B (en) 1995-09-27
IL112384A (en) 1998-08-16
GB9401090D0 (en) 1994-03-16
IL112384A0 (en) 1995-03-30
HK1013286A1 (en) 1999-08-20
LV11690A (lv) 1997-02-20
HUT74943A (en) 1997-03-28
BG62733B1 (bg) 2000-06-30
HRP950023B1 (en) 2000-10-31
UY23893A1 (es) 1995-07-11
LU91017I2 (fr) 2003-05-26
AU1574895A (en) 1995-08-08
MX9602904A (es) 1997-12-31
EP0740668B1 (en) 1998-07-29
CZ211696A3 (en) 1997-06-11
JPH09508113A (ja) 1997-08-19
CN1143963A (zh) 1997-02-26
ATE169018T1 (de) 1998-08-15
JP4347125B2 (ja) 2009-10-21
SK280879B6 (sk) 2000-08-14
SV1995000002A (es) 1995-10-04
MA23433A1 (fr) 1995-10-01
AU7391298A (en) 1998-08-20
PL315559A1 (en) 1996-11-12
US6127542A (en) 2000-10-03
CA2181377A1 (en) 1995-07-27
HU9601982D0 (en) 1996-09-30
CN1070492C (zh) 2001-09-05
NZ279199A (en) 1998-01-26
US5859006A (en) 1999-01-12

Similar Documents

Publication Publication Date Title
BR9506559C8 (pt) compostos de derivados tetracíclicos, isômero cis de derivados tetracíclicos, e, composição farmacêutica
BR9913824A (pt) Combinações de inibidores cìclicos, tetracìclicos de fosfodiesterase especìfica de gmp, com agentes terapêuticos adicionais
BR0212864A (pt) Derivados de 1,6-naftiridina como antidiabéticos
PL398536A1 (pl) Pochodne pirazolu i kompozycje farmaceutyczne zawierające je oraz ich zastosowanie do leczenia HIV
EA199700209A1 (ru) ПРОИЗВОДНЫЕ ИМИДАЗО[1,2-a]ПИРИДИНА
BR0113448A (pt) Composto da fórmula ou um sal ou solvato deste ou um derivado destes fisiologicamente funcional, composição farmacêutica, uso do composto ou de um sal ou solvato deste ou de um derivado destes fisiologicamente funcional, e , métodos para tratar uma condição ou estado de doença mediados pela p38 quinase ou mediados pelas citoquinas, e mediados pela jnk quinase ou mediados pelas citoquinas, e ,para tratar duas ou mais condições ou doenças independentemente mediadas pela atividade da p38 e da jnk quinase
RU2005123394A (ru) Диаминовые производные
DE69324151D1 (de) Inhibitoren des arginin-ketoamid-enzyms
BR0015193A (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratamento de uma condição associada com trasmissão reduzida de nicotina, para tratamento ou profilaxia de distúrbios psicóticos ou distúrbios de deterioração intelectual e para tratamento ou profilaxia de doenças ou condições humanas
EA200400223A1 (ru) Новые производные 2h-пиридазин-3-она, фармацевтические композиции, содержащие эти производные, и способ получения активного ингредиента
CA2437718A1 (en) Carboline derivatives
BR9807950A (pt) Composto, composição farmacêutica, uso de um composto, e, processos para tratar ou reduzir o risco de doenças ou condições humanas, o risco de doença inflamatória o risco da dor e para a preparação de um composto
EA200400936A1 (ru) ГЕТЕРОАРИЛЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 2-ПИРИДИНИЛ- И 2-ПИРИМИДИНИЛ-6,7,8,9-ТЕТРАГИДРОПИРИМИДО[1,2-a]ПИРИМИДИН-4-ОНА
NO930499L (no) Benzimidazolderivater, fremgangsmaate for deres fremstilling og deres anvendelse
RU94038256A (ru) Производные пиразолопиримидина, способ их получения, фармацевтические композиции на их основе
EP1120409A4 (en) 2,3-DISUBSTITUTED PYRIDE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR ACTIVE SUBSTANCE PREPARATIONS CONTAINING IT AND INTERMEDIATE PRODUCTS FOR THE PRODUCTION
IT1201934B (it) Derivati della paromomicina
DK0966462T3 (da) Heterocykliske forbindelser, der er egnede som oxidosqualencyklaseinhibitorer
AU759604B2 (en) Inhibitor for 20-hete-yielding enzyme
FR2655043B1 (fr) Nouveaux derives du thiophene, leur procede de preparation et les compositions pharmaceutiques les renfermant.
NO985974L (no) Piperidineddiksyrederivater og deres anvendelse ved behandling av trombose-sykdommer
EP1806136A4 (en) MEDICAL COMPOSITION PREVENTING THE TRANSITION TO OPERATIVE TREATMENT IN PROSTATE HYPERTROPHY
ATE380028T1 (de) Mittel zur anregung des appetits und mittel zur behandlung von anorexie
DK0419844T3 (da) N-Hydroxy-dibenz(b,e)oxepin-alkylaminer og -alkansyreamider, beslægtede heterocycliske analoger, fre mgangsmåde til deres fremstilling og deres anvendelse ved fremstilling af lægemidler
DE60321700D1 (de) Pyrazolderivate und deren verwendung als therapeutische mittel für durch hiv vermittelte krankheiten

Legal Events

Date Code Title Description
PC Transfer

Free format text: ICOS CORPORATION (US)

HHT Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: republication

Free format text: REFERENCIA RPI 1460; CODIGO (25.1); ITEM (71)

FB36 Technical and formal requirements: requirement - article 36 of industrial property law
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent

Free format text: INPI-52400.061594/2013 ORIGEM: JUIZO DA 013A VARA FEDERAL DO RIO DE JANEIRO PROCESSO NO 0132351-11.2013.4.02.5101 ACAO DE NULIDADE DAS PATENTES SUBMETIDAS AO MAILBOX (ART. 229, PARAGRAFO UNICO DA LPI); ALTERNATIVAMENTE, A DECRETACAO DA NULIDADE PARCIAL PARA CORRECAO DO PRAZO DE VIGENCIA; SUBSIDIARIAMENTE, CASO SE ENTENDA NAO SER O CASO DE NULIDADE, A CORRECAO DO ATO ADMINISTRATIVO PARA ADEQUACAO DA VIGENCIA DAS PATENTES. AUTOR: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI REU: GLAXO GROUP LIMITED, GLAXO WELLCOME INC, IMMUNOTECH DEVELOPMENTS INC, IVAX INTERNACIONAL GMBH.

B19A Notification of judicial decision: notification of judicial decision

Free format text: INPI-52400.002459/2015-23 09A VARA FEDERAL DO RIO DE JANEIRO 0000524-03.2015.4.02.5101 TRIBUNAL REGIONAL FEDERAL DA 2A REGIAO PROC. NO 00003601520154020000 AGRAVO DE INSTRUMENTO APELANTE: EUROFARMA LABORATORIOS S.A. APELADO: ELI LILLY DO BRASIL LTDA. E OUTROS DECISAO: DEFIRO A ANTECIPACAO DE TUTELA RECURSAL, NOS TERMOS DO ITEM I, B DO PEDIDO (FL. 11) PARA SUSPENDER OS EFEITOS DA PATENTE PI9506559-8 IMEDIATAMENTE APOS O SEU PRAZO DE EXPIRACAO, A SABER, 19.01.2014, ATE DECISAO FINAL.

B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent

Free format text: INPI-52400.041642/2015 ORIGEM: JUIZO DA 09A VARA FEDERAL DO RIO DE JANEIRO PROCESSO NO 0000524-03.2015.4.02.5101 ACAO DE NULIDADE SOB O RITO ORDINARIO, COM PEDIDO LIMINAR, INAUDITA ALTERA PARS AUTOR: EUROFARMA LABORATORIOS S.A. REU: ICOS CORPORATION, E ELI LILLY DO BRASIL LTDA, E INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI

B19A Notification of judicial decision: notification of judicial decision

Free format text: INPI-52400.041642/2015 SECAO JUDICIARIA DO RIO DE JANEIRO 9A VARA FEDERAL DO RIO DE JANEIRO PROCESSO NO 0000524-03.2015.4.02.5101 AUTOR: EUROFARMA LABORATORIOS S.A REU: ICOS CORPORATION, ELI LILLY DO BRASIL LTDA E INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL INPI DECISAO: ISTO POSTO, JULGO EXTINTO SEM RESOLUCAO DO MERITO O PROCESSO, NOS TERMOS DO ART. 485, VI DO CPC.

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 15/03/2015

B19A Notification of judicial decision: notification of judicial decision

Free format text: INPI-52400.041642/2015 SECAO JUDICIARIA DO RIO DE JANEIRO - 9A VARA FEDERAL PROCESSO NO 0000524-03.2015.4.02.5101 AUTOR: EUROFARMA LABORATORIOS S/A REU: ICOS CORPORATION, ELI LILLY DO BRASIL LTDA E INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI DECISAO: CONFIRMO E MANTENHO A TUTELA PROVISORIA DE URGENCIA CONCEDIDA NO ACORDAO DE FLS. 800/818, FICANDO MANTIDO O PRAZO DE VIGENCIA DA PI 9506559-8 EM 19/01/2015, COMO DISPOSTO NO ARTIGO 40 CAPUT E ARTIGO 229 PARAGRAFO UNICO, AMBOS DA LEI NO9.279/96. PROCEDA O INPI AS ANOTACOES NECESSARIAS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]
B21J Extinguishment of a patent or of a certificate of addition of invention: republication
B19A Notification of judicial decision: notification of judicial decision

Free format text: INPI NO 52400.041642/2015-44 09A VARA FEDERAL DO RIO DE JANEIRO NUP: 00848.000504/2020-10 (REF. 00848.000052/2015-17) INTERESSADOS: EUROFARMA LABORATORIOS S.A. E OUTROS DECISAO: ADOTAR AS PERTINENTES PROVIDENCIAS ADMINISTRATIVAS NO SENTIDO DE QUE O PRAZO DE VIGENCIA DA PATENTE PI 9506559-8 PASSE A SER 15/03/2015.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: CONFORME DETERMINADO NO PROCESSO INPI NO 52400.041642/2015-44 09A VARA FEDERAL DO RIO DE JANEIRO NUP: 00848.000504/2020-10 (REF. 00848.000052/2015-17) ALTERAR A DATA DE VIGENCIA DA PATENTE PARA 15/03/2015.